Extending the role of antithrombotic agents: An example based on the low-molecular-weight heparin, tinzaparinHAINER, James W; SPROGEL, Per; LINDENSTROEM, Ewa et al.Seminars in thrombosis and hemostasis. 2004, Vol 30, pp 3-9, issn 0094-6176, 7 p., SUP1Conference Paper

Effects of Heparin and its 6-O- and 2-O-desulfated derivatives with low anticoagulant activity on proliferation of human neural stem/progenitor cellsMORI, Hideki; KANEMURA, Yonehiro; ONAYA, Junichi et al.Journal of bioscience and bioengineering. 2005, Vol 100, Num 1, pp 54-61, issn 1389-1723, 8 p.Article

Guidelines on the use and monitoring of heparinBAGLIN, T; BARROWCLIFFE, T. W; COHEN, A et al.British journal of haematology. 2006, Vol 133, Num 1, pp 19-34, issn 0007-1048, 16 p.Article

Bridging therapy and oral anticoagulation: current and future prospectsSPYROPOULOS, Alex C.Current opinion in hematology. 2010, Vol 17, Num 5, pp 444-449, issn 1065-6251, 6 p.Article

Heparin-induced thrombocytopenia following hip and knee arthroplastyCRAIK, Johnathan D; COBB, Andrew G.British journal of haematology. 2013, Vol 161, Num 2, pp 255-261, issn 0007-1048, 7 p.Article

The anticoagulant capacity of plasmatic unfractionated heparin decreases at 23°CSTIEF, Thomas W.Blood coagulation & fibrinolysis. 2007, Vol 18, Num 2, pp 209-212, issn 0957-5235, 4 p.Article

Amount of bleeding and hematoma size in the collagenase-induced intracerebral hemorrhage rat modelTERAI, Kazuhiro; SUZUKI, Masanori; SASAMATA, Masao et al.Neurochemical research. 2003, Vol 28, Num 5, pp 779-785, issn 0364-3190, 7 p.Article

Clinical use of unfractionated heparin therapy in children: time for change?NEWALL, Fiona; IGNJATOVIC, Vera; JOHNSTON, Linda et al.British journal of haematology. 2010, Vol 150, Num 6, pp 674-678, issn 0007-1048, 5 p.Article

The effect of taurolidine on experimental thrombus formationKAPTANOGLU, Levent; KUCUK, Hasan Fehmi; COLAK, Elif et al.European journal of pharmacology. 2008, Vol 578, Num 2-3, pp 238-241, issn 0014-2999, 4 p.Article

Differentiating Low-Molecular-Weight Heparins Based on Chemical, Biological, and Pharmacologic Properties : Implications for the Development of Generic Versions of Low-Molecular-Weight HeparinsJESKE, Walter P; WALENGA, Jeanine M; HOPPENSTEADT, Debra A et al.Seminars in thrombosis and hemostasis. 2008, Vol 34, Num 1, pp 74-85, issn 0094-6176, 12 p.Article

MINIMAL HEPARIN COFACTOR ACTIVITY IN DISSEMINATED INTRAVASCULAR COAGULATION AND CIRRHOSIS.BRAUNSTEIN KM; EURENIUS K.1976; AMER. J. CLIN. PATHOL.; U.S.A.; DA. 1976; VOL. 66; NO 3; PP. 488-494; BIBL. 21 REF.Article

Heparin-induced thrombocytopenia : What clinicians need to knowCHONG, Beng H; ISAACS, Arend.Thrombosis and haemostasis. 2009, Vol 101, Num 2, pp 279-283, issn 0340-6245, 5 p.Article

Activation of heparin cofactor II by heparin and dermatan sulfateTOLLEFSEN, D. M.Nouvelle revue française d'hématologie. 1984, Vol 26, Num 4, pp 233-237, issn 0029-4810Article

A CATALYTIC ROLE FOR HEPARIN. EVIDENCE FOR A TERNARY COMPLEX OF HEPARIN COFACTOR THROMBIN AND HEPARINPOMERANTZ MW; OWEN WG.1978; BIOCHIM. BIOPHYS. ACTA; NLD; DA. 1978; VOL. 535; NO 1; PP. 66-77; BIBL. 25 REF.Article

Comparing methods of establishing the aPTT therapeutic range of heparinLIEPMAN, Claire I; KOERBER, John M; MATTSON, Joan C et al.The Annals of pharmacotherapy. 2003, Vol 37, Num 6, pp 794-798, issn 1060-0280, 5 p.Article

Effect of site of venous Protamine administration, previously alleged risk factors, and preoperative use of aspirin on acute protamine-induced pulmonary vasoconstrictionCOMUNALE, Mark E; MASLOW, Andrew; ROBERTSON, Linda K et al.Journal of cardiothoracic and vascular anesthesia. 2003, Vol 17, Num 3, pp 309-313, issn 1053-0770, 5 p.Article

Heparin to pentasaccharide and beyond: The end is not in sightMESSMORE, Harry L; WEHRMACHER, William H; COYNE, Erwin et al.Seminars in thrombosis and hemostasis. 2004, Vol 30, pp 81-88, issn 0094-6176, 8 p., SUP1Conference Paper

A prospective analysis of heparin-platelet factor 4 antibodies in pregnant women treated with the low-molecular-weight heparin, dalteparinGERDSEN, Frank; LUXEMBOURG, Beate; LANGER, Florian et al.Blood coagulation & fibrinolysis. 2008, Vol 19, Num 6, pp 477-481, issn 0957-5235, 5 p.Article

Treatment of 51 pregnancies with danaparoid because of heparin intoleranceLINDHOFF-LAST, Edelgard; KREUTZENBECK, Hans-Joachim; MAGNANI, Harry N et al.Thrombosis and haemostasis. 2005, Vol 93, Num 1, pp 63-69, issn 0340-6245, 7 p.Article

Effects of nadroparin, enoxaparin, and unfractionated heparin on endogenous factor Xa and lla formation and on thrombelastometry profilesCVIRN, Gerhard; WAGNER, Thomas; JUERGENS, Guenther et al.Blood coagulation & fibrinolysis. 2009, Vol 20, Num 1, pp 71-77, issn 0957-5235, 7 p.Article

Simplified chromogenic substrate assay for low molecular weight heparinHANDELAND, G.Thrombosis research. 1986, Vol 42, Num 1, pp 105-108, issn 0049-3848Article

Les héparines de bas poids moléculaire/Réunion du Groupe d'Etudes sur l'Hémostase et la Thrombose de la Société Française d'Hématologie, Nancy, 21-22 novembre 1987 = Heparins of low molecular weight/meeting of «groupe d'Etudes sur l'hémostase et la thrombose de la Société Française d'Hématologie», Nancy, 21-22 November 1987ALEXANDRE, P; SAMAMA, M.Journal des maladies vasculaires. 1987, Vol 12, pp 55-151, issn 0398-0499, suppl. BConference Proceedings

Etude de la neutralisation in vitro et in vivo d'une fraction de bas poids moléculaire d'héparine CY 216 par la protamine = In vitro and in vivo neutralisation of a low molecular weight heparin fraction (CY 216) by protamine sulfateDOUTREMEPUICH, C; BONINI, F; MASSE, A et al.Annales pharmaceutiques françaises. 1986, Vol 44, Num 1, pp 65-72, issn 0003-4509Article

Héparine de bas poids moléculaire et hémodialyse = Low molecular weight heparin and hemodialysisDIEVAL, J; MORINIERE, P; ROUSSEL, R et al.Angéiologie (Paris). 1986, Vol 38, Num 4, pp 147-156, issn 0003-3049Article

The new understanding of the drug heparinJAQUES, L. B.Chest. 1985, Vol 88, Num 5, pp 751-754, issn 0012-3692Article